Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

Featured News
Lassa Virus under a microscope

The GW VRU was a site for the phase 1, double-blind clinical trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever. A total of 114 adults were enrolled, and no serious vaccine-related adverse events were reported. The vaccine had immunogenicity across the study population in the United States and Liberia.

 

 

Photo Credit: AMI IMAGES / SCIENCE PHOTO LIBRARY

Click here to read more!
vaccine

Latest News

Picture of small pox with the outer and inner core
Results show safety and immunogenicity of fractional doses of the MVA-BN mpox vaccine
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
An omicron COVID virus. A gray virus with red and orange projections.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
This is an HIV antibody with a yellow core and pink outer shell.
Targeting HIV broadly neutralizing antibody precursors with precision in humans.
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…